Medeiros Márcia M, Fotoran Wesley L, dalla Martha Rosimeire C, Katsuragawa Tony H, Pereira da Silva Luiz Hildebrando, Wunderlich Gerhard
Department of Parasitology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil.
BMC Infect Dis. 2013 Dec 28;13:608. doi: 10.1186/1471-2334-13-608.
Antibodies have an essential role in the acquired immune response against blood stage P. falciparum infection. Although several antigens have been identified as important antibody targets, it is still elusive which antigens have to be recognized for clinical protection. Herein, we analyzed antibodies from plasmas from symptomatic or asymptomatic individuals living in the same geographic area in the Western Amazon, measuring their recognition of multiple merozoite antigens.
Specific fragments of genes encoding merozoite proteins AMA1 and members of MSP and EBL families from circulating P. falciparum field isolates present in asymptomatic and symptomatic patients were amplified by PCR. After cloning and expression of different versions of the antigens as recombinant GST-fusion peptides, we tested the reactivity of patients' plasmas by ELISA and the presence of IgG subclasses in the most reactive plasmas.
11 out of 24 recombinant antigens were recognized by plasmas from either symptomatic or asymptomatic infections. Antibodies to MSP9 (X2(DF=1) = 9.26/p = 0.0047) and MSP5 (X2(DF=1) = 8.29/p = 0.0069) were more prevalent in asymptomatic individuals whereas the opposite was observed for MSP1 block 2-MAD20 (X2(DF=1) = 6.41/p = 0.0206, Fisher's exact test). Plasmas from asymptomatic individuals reacted more intensely against MSP4 (U = 210.5, p < 0.03), MSP5 (U = 212, p < 0.004), MSP9 (U = 189.5, p < 0.002) and EBA175 (U = 197, p < 0.014, Mann-Whitney's U test). IgG1 and IgG3 were predominant for all antigens, but some patients also presented with IgG2 and IgG4. The recognition of MSP5 (OR = 0.112, IC95% = 0.021-0.585) and MSP9 (OR = 0.125, IC95% = 0.030-0.529, cross tab analysis) predicted 8.9 and 8 times less chances, respectively, to present symptoms. Higher antibody levels against MSP5 and EBA175 were associated by odds ratios of 9.4 (IC95% = 1.29-69.25) and 5.7 (IC95% = 1.12-29.62, logistic regression), respectively, with an asymptomatic status.
Merozoite antigens were targets of cytophilic antibodies and antibodies against MSP5, MSP9 and EBA175 were independently associated with decreased symptoms.
抗体在获得性免疫反应对抗恶性疟原虫血液阶段感染中起关键作用。尽管已鉴定出几种抗原为重要的抗体靶点,但对于临床保护而言,究竟哪些抗原必须被识别仍不清楚。在此,我们分析了来自生活在亚马逊西部同一地理区域的有症状或无症状个体血浆中的抗体,测定了它们对多种裂殖子抗原的识别情况。
通过聚合酶链反应(PCR)扩增来自无症状和有症状患者体内循环的恶性疟原虫野外分离株中编码裂殖子蛋白AMA1以及MSP和EBL家族成员的基因的特定片段。在将不同版本的抗原克隆并表达为重组谷胱甘肽S-转移酶(GST)融合肽后,我们通过酶联免疫吸附测定(ELISA)检测患者血浆的反应性以及反应性最强的血浆中IgG亚类的存在情况。
24种重组抗原中的11种被有症状或无症状感染患者的血浆识别。针对MSP9(X2(自由度=1)=9.26/p=0.0047)和MSP5(X2(自由度=1)=8.29/p=0.0069)的抗体在无症状个体中更为普遍,而MSP1第2区-MAD20则相反(X2(自由度=1)=6.41/p=0.0206,Fisher精确检验)。无症状个体的血浆对MSP4(U=210.5,p<0.03)、MSP5(U=212,p<0.004)、MSP9(U=189.5,p<0.002)和EBA175(U=197,p<0.014,曼-惠特尼U检验)的反应更强。IgG1和IgG3在所有抗原中占主导地位,但一些患者也出现了IgG2和IgG4。对MSP5(比值比(OR)=0.112,95%置信区间(IC95%)=0.021-0.585)和MSP9(OR=0.125,IC95%=0.030-0.529,交叉表分析)的识别分别预测出现症状的几率降低8.9倍和8倍。针对MSP5和EBA175的较高抗体水平分别与无症状状态的比值比为9.4(IC95%=1.29-69.25)和5.7(IC95%=1.12-29.62,逻辑回归)相关。
裂殖子抗原是嗜细胞抗体的靶点,针对MSP5、MSP9和EBA175的抗体与症状减轻独立相关。